Publications by authors named "Huu Nguyen Nguyen"

The emergence of multicancer early detection (MCED) tests holds promise for improving early cancer detection and public health outcomes. However, positive MCED test results require confirmation through recommended cancer diagnostic imaging modalities. To address these challenges, we have developed a consultation and work-up protocol for definitive diagnostic results post MCED testing, named SPOT-MAS.

View Article and Find Full Text PDF
Article Synopsis
  • The SPOT-MAS assay detects five common cancers in Vietnam by analyzing circulating tumor DNA in blood samples.
  • It was validated in the K-DETEK clinical trial involving 2,795 participants across 14 sites, showing a 60% positive predictive value and 83.3% accuracy in identifying tumor locations.
  • The study suggests that SPOT-MAS can be used as a complementary method for early cancer detection, potentially leading to timely treatment opportunities.
View Article and Find Full Text PDF

Background: A heterozygous natriuretic peptide receptor 2 (NPR2) gene c.2455C>T mutation was identified as a cause of familial idiopathic short stature (ISS). Only two cases with this mutation were reported previously, and the probands with ISS had no organ system defects.

View Article and Find Full Text PDF
Article Synopsis
  • * This study analyzed NIPT data from 2,683 pregnant Vietnamese women, identifying over 8 million genetic variants, with 8.2% being unique to this population.
  • * The findings revealed 24,487 disease-related genetic variants and significant differences in allele frequency compared to other populations, underscoring the necessity for studies focused on the Vietnamese community.
View Article and Find Full Text PDF

The identification and quantification of actionable mutations are critical for guiding targeted therapy and monitoring drug response in colorectal cancer. Liquid biopsy (LB) based on plasma cell-free DNA analysis has emerged as a noninvasive approach with many clinical advantages over conventional tissue sampling. Here, we developed a LB protocol using ultra-deep massive parallel sequencing and validated its clinical performance for detection and quantification of actionable mutations in three major driver genes ( and ).

View Article and Find Full Text PDF